Total n = 18 | Interventionn = 11 | Waitlist n = 7 | p-value* | |
---|---|---|---|---|
Gender, n (%) | ||||
Male | 12 (67%) | 9 (82%) | 3 (43%) | |
Female | 6 (33%) | 2 (18%) | 4 (57%) | |
Age, M (SD) | 66 (8.26) | 68 (7.72) | 62 (8.34) | .17 |
PD duration (M years, SD) | 5.12 (4.61) | 5.70 (5.50) | 4.29 (3.15) | .55 |
Age of PD onset, M (SD) | 61.82 (7.47) | 64.10 (7.82) | 58.57 (6.00) | .13 |
Mean H&Y stage | II | II | II | |
Taking antidepressants, n (%) | 11 (61%) | 6 (55%) | 5 (74%) | |
DSM-IV-TR diagnosis, n (%) | ||||
Generalised anxiety | 12 (66%) | 8 (73%) | 4 (57%) | |
Panic attacks and/or disorder | 7 (39%) | 4 (35%) | 3 (43%) | |
Major depressive disorder | 6 (33%) | 2 (18%) | 4 (57%) | |
Dysthymia | 6 (33%) | 3 (27%) | 3 (43%) | |
Social anxiety | 4 (22%) | 1 (9%) | 3 (43%) | |
Posttraumatic stress disorder | 1 (5%) | 0 | 1 (14%) | |
Primary outcomes, M (SD) | ||||
DASS-D | 10.44 (4.23) | 10.09 (3.73) | 10.71 (5.41) | .99 |
DASS-A | 9.06 (3.35) | 9.64 (2.01) | 8.57 (4.61) | .72 |
DASS-S | 9.78 (3.83) | 10.64 (3.26) | 10.00 (4.28) | .56 |
Secondary outcomes, M (SD) | ||||
PDQ-39 | 34.97 (13.07) | 36.03 (12.62) | 28.48 (16.15) | .27 |
CCL-D | 30.29 (13.30) | 31.22 (15.50) | 24.49 (14.12) | .32 |
CCL-A | 32.41 (12.19) | 32.01 (10.51) | 29.46 (14.00) | .62 |